| Starts: | Tuesday March 23, 2010 at 8:00am |
|---|---|
| Ends: | Friday March 26, 2010 at 5:00pm |
| Event Type: | Conference |
| Region: | Greater Boston Area |
| Location: |
tbc - Boston, MA - US |
| Price: | https://secure.terrapinn.com/V5/rCalc.aspx?E=3319 |
| Website: | http://www.healthnetworkcommunications.com/2010/lpddusa |
| Industry: | pharmaceuticals |
| Keywords: | Late Phase, Phase Ii Ib, Phase Iv, Clinical Trials, Pharmaceutical, Biotech, Strategy, Conference, Approved Drug, Safety, Marketed Drugs, Patient, Surveillance, Phase Ii, Risk, Speed, Efficiency |
| Intended For: | clinical trials, research, post marketing surveillance, medical affairs, pharmacoepidemiology, investigator sponsored studies, clinical data management, clnical trial registration, results databases, pharmacovigilance, risk management |
| Organization: | Health Network Communications |
Late phase drug development is growing at around 20% annually, exceeding the growth rate of Phase II and III Trials. In excess of $12 billion is currently being spent on Phase IIIb/IV studies as public concerns on the safety of approved drugs prevail together with the need to evaluate real world safety and effectiveness of marketed drugs. More than ever before there is the urgent need to detect, quantify and communicate patient risk with speed and efficiency.
As a result, Health Network Communications is delighted to announce the first ever strategic forum in the US addressing the major challenges in conducting strategic and compliant late stage studies.